A:NYE-Agilent Technologies, Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 72.67

Change

+1.76 (+2.48)%

Market Cap

USD 21.96B

Volume

1.40M

Average Target Price

USD 80.27 (+10.45%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, and software as a service, as well as asset management and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. The company was founded in 1999 and is headquartered in Santa Clara, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

+10.62 (+3.87%)

USD113.65B 31.08 19.20
DHR-PA Danaher Corporation

+11.33 (+1.06%)

USD97.88B 262.49 166.66
DHR Danaher Corporation

+2.24 (+1.62%)

USD96.58B 34.18 22.53
PHG Koninklijke Philips N.V

+1.81 (+4.64%)

USD34.13B 24.67 N/A
IQV IQVIA Holdings Inc

+5.84 (+5.45%)

USD20.66B 111.60 17.11
MTD Mettler-Toledo International I..

+26.62 (+4.04%)

USD15.80B 29.32 21.61
LH Laboratory Corporation of Amer..

+3.24 (+2.52%)

USD12.52B 15.41 9.93
WAT Waters Corporation

+2.78 (+1.50%)

USD11.52B 21.33 15.76
DGX Quest Diagnostics Incorporated

-0.02 (-0.02%)

USD10.58B 12.63 9.30
QGEN QIAGEN N.V

+0.02 (+0.05%)

USD9.30B 35.49 20.89

ETFs Containing A

Symbol Name Weight Mer Price(Change) Market Cap
GNOM Global X Genomics & Biote.. 4.25 % 0.68 %

+0.20 (+1.58%)

USD0.02B
FIW First Trust Water ETF 4.17 % 0.55 %

+1.64 (+3.53%)

USD0.53B
WELL:LSE HAN-GINS Indxx Healthcare.. 3.54 % 0.00 %

N/A

USD3.93M

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.82% 65% D 70% C-
Dividend Return 0.21% 67% D+ 7% F
Total Return -14.61% 65% D 70% C-
Trailing 12 Months  
Capital Gain -9.59% 47% F 68% D+
Dividend Return 1.06% 57% F 23% F
Total Return -8.53% 47% F 66% D
Trailing 5 Years  
Capital Gain 74.90% 87% B+ 93% A
Dividend Return 6.74% 63% D 24% F
Total Return 81.64% 80% B- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 15.77% 50% F 86% B
Dividend Return 0.79% 50% F 18% F
Total Return 16.57% 56% F 85% B
Risk Return Profile  
Volatility (Standard Deviation) 17.13% 50% F 46% F
Risk Adjusted Return 96.71% 56% F 85% B
Market Capitalization 21.96B 80% B- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.34 59% F 16% F
Price/Book Ratio 4.54 29% F 12% F
Price / Cash Flow Ratio 21.51 45% F 11% F
EV/EBITDA 18.37 39% F 14% F
Management Effectiveness  
Return on Equity 15.46% 75% C 77% C+
Return on Invested Capital 18.53% 80% B- 91% A-
Return on Assets 6.84% 85% B 85% B
Debt to Equity Ratio 37.62% 68% D+ 71% C-
Technical Ratios  
Short Ratio 1.82 58% F 50% F
Short Percent 1.83% 76% C 79% C+
Beta 1.33 30% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.